JW Pharmaceutical Corp Working Capital to Net Assets Ratio
JW Pharmaceutical Corp working capital to net assets ratio. JW Pharmaceutical Corp (001067) has a Working Capital to Net Assets ratio of 31.6% as of September 2025. Working capital of ₩111.85 Billion (current assets of ₩331.96 Billion minus current liabilities of ₩220.10 Billion) is measured against net assets of ₩354.10 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check JW Pharmaceutical Corp (001067) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of JW Pharmaceutical Corp (2014–2024)
Working capital to net assets ratio of JW Pharmaceutical Corp from 2014 to 2024. This chart shows how JW Pharmaceutical Corp's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2014 to 2024. As of September 2025, the ratio stands at 31.6%, reflecting working capital of ₩111.85 Billion against net assets of ₩354.10 Billion KRW. See operational self-sufficiency of JW Pharmaceutical Corp to measure how many days the company can operate on defensive assets alone.
JW Pharmaceutical Corp Working Capital to Net Assets Ratio by Year (2014–2024)
JW Pharmaceutical Corp working capital to net assets ratio by year from 2014 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for JW Pharmaceutical Corp from 2014 to 2024, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of JW Pharmaceutical Corp.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 29.7% | ₩97.80 Billion | ₩329.49 Billion | ₩306.41 Billion | ₩208.62 Billion | ▼ -4.7 pp |
| 2023 | 34.3% | ₩91.16 Billion | ₩265.44 Billion | ₩378.09 Billion | ₩286.93 Billion | ▲ +14.3 pp |
| 2022 | 20.1% | ₩45.33 Billion | ₩225.76 Billion | ₩425.46 Billion | ₩380.13 Billion | ▼ -24.4 pp |
| 2021 | 44.4% | ₩83.77 Billion | ₩188.54 Billion | ₩366.45 Billion | ₩282.68 Billion | ▲ +13.3 pp |
| 2020 | 31.1% | ₩64.58 Billion | ₩207.47 Billion | ₩299.33 Billion | ₩234.75 Billion | ▲ +6.3 pp |
| 2019 | 24.8% | ₩57.07 Billion | ₩230.09 Billion | ₩335.06 Billion | ₩277.98 Billion | ▼ -31.1 pp |
| 2018 | 56.0% | ₩145.54 Billion | ₩260.11 Billion | ₩373.91 Billion | ₩228.37 Billion | ▲ +5.4 pp |
| 2017 | 50.5% | ₩136.83 Billion | ₩270.78 Billion | ₩411.37 Billion | ₩274.54 Billion | ▼ -9.1 pp |
| 2016 | 59.6% | ₩164.67 Billion | ₩276.31 Billion | ₩422.64 Billion | ₩257.98 Billion | ▲ +8.4 pp |
| 2015 | 51.2% | ₩115.39 Billion | ₩225.41 Billion | ₩376.17 Billion | ₩260.78 Billion | ▼ -8.8 pp |
| 2014 | 60.0% | ₩132.06 Billion | ₩220.02 Billion | ₩343.50 Billion | ₩211.44 Billion | — |